Profil
Patricia A.
Oto has been Vice President-Regulatory Affairs of Onyx Pharmaceuticals, Inc. since December 2006.
She was Vice President of Regulatory Affairs and Quality Assurance for Anesiva, Inc. from 2001 to 2006.
Prior to joining Anesiva, Ms. Oto was Senior Director of Regulatory Affairs of Corixa Corporation and Director of Regulatory Affairs and Quality Assurance for Coulter.
Previously, she worked for Genentech, Inc. Ms. Oto received her BS degree in Pharmacy from the University of New Mexico.
Ehemalige bekannte Positionen von Patricia J. Oto
| Unternehmen | Position | Ende |
|---|---|---|
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | General Counsel | 01.01.2006 |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | General Counsel | - |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | General Counsel | - |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | General Counsel | - |
Ausbildung von Patricia J. Oto
| The University of New Mexico | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Anesiva, Inc.
Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | Health Technology |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |